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Epigenetic silencing through promoter hypermethylation is an important hallmark for the inactivation of
tumor-related genes in carcinogenesis. Here we identified the ATP-binding cassette sub-family Bmember 4
(ABCB4) as a novel epigenetically silenced target gene. We investigated the epigenetic regulation of ABCB4
in 26 human lung, breast, skin, liver, head and neck cancer cells lines and in primary cancers bymethylation
and expression analysis. Hypermethylation of the ABCB4 CpG island promoter occurred in 16 out of 26
(62%) human cancer cell lines. Aberrant methylation of ABCB4 was also revealed in 39% of primary lung
cancer and in 20% of head and neck cancer tissues. In 37% of primary lung cancer samples, ABCB4
expression was absent. For breast cancer a significant hypermethylation occurred in tumor tissues (41%)
compared to matching normal samples (0%, p 5 0.002). Silencing of ABCB4 was reversed by
5-aza-2’-deoxycytidine and zebularine treatments leading to its reexpression in cancer cells. Overexpression
of ABCB4 significantly suppressed colony formation and proliferation of lung cancer cells.
Hypermethylation of Abcb4 occurred also in murine cancer, but was not found in normal tissues. Our
findings suggest that ABCB4 is a frequently silenced gene in different cancers and it may act tumor
suppressivly in lung cancer.
E
pigenetic mechanisms play an important role for initiating and maintaining memory effects on gene
expression. In mammalians, the epigenetic regulation is essential for normal development by regulating
gene imprinting, X-chromosome inactivation and transcriptional inactivation of repetitive genomic el-
ements. Moreover, epigenetic inactivation of tumor suppressor genes is frequently observed during carcinoge-
nesis1. Especially hypermethylation of promoters harboring a CpG island is a hallmark of gene silencing during
malignant transformation. CpG islands are sequences greater than 500 bp ofGC-rich andCpG-dense elements in
the genome. About 70% of known genes harbor a CpG island within the promoter and the first exon. During
tumorigenesis CpG islands of the promoter regions of tumor suppressive genes become hypermethylated and this
aberrant methylation is accompanied by the formation of repressive chromatin and gene inactivation. The most
frequently epigenetically inactivated tumor suppressor genes are the cyclin-dependent kinase inhibitor 2A (p16)
and the Ras association domain family (RASSF) genes1–3.
The ABC (ATP-binding cassette) transporters are a large family of transmembrane proteins, with seven
subfamilies that are designated A to G4. These subfamilies are also termed ABC1, MDR/TAP, MRP, ALD,
OABP, GCN20 and White, respectively. ABCB4 (ATP-binding cassette, sub-family B, member 4) belongs to
theMDR/TAP subfamily and the protein is also known asMDR2 orMDR3 (multi drug resistance). ABC proteins
transport various molecules (e.g. xenobiotics, drugs, lipid and other metabolic products) across the plasma and
intracellular membranes4. ABCB4 is such a transporter and a member of the p-glycoprotein family of membrane
proteins and translocates phospholipids (e.g. phosphatidylcholine) from the inner to the outer membrane of the
hepatocyte5. The exact function of ABCB4 has not been determined in detail, however it is not involved in drug
resistance of ovarian carcinoma cells to cisplatin6.
The ABCB4 gene is localized on chromosome 7 at q21.12 (Fig. 1). Genetic alterations of ABCB4 are associated
with progressive familial intrahepatic cholestasis type 3, low phospholipid associated cholelithiasis and also found
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ABC transporter transmembrane regions and two ATP-binding cas-
sette domains (Fig. 1A). In accordance with its function, ABCB4 is
highly expressed in human liver, but lower mRNA levels were also
found in other normal tissues13. The gene promoter of ABCB4 har-
bors a CpG island that is usually unmethylated in normal cells
(Fig. 1A)14. The epigenetic regulation ABCB4 in cancer has not been
analyzed in detail. In our study we report frequent hypermethylation
ofABCB4 in human cancers. Interestingly, we also observed a growth
suppressive function of ABCB4 in lung cancer cells.
Results
Methylation ofABCB4 occurred in distinct human cancer entities.
We have performed a genome wide methylation screen (Infinium
HumanMethylation450 BeadChip) in three lung cancer cell lines
(A549, A427, H322) and normal human bronchial epithelial cells
(NHBEC) and found a hypermethylation of ABCB4 at six CpG
sites in its CpG island promoter in A549, A427 and H322
compared to NHBEC (21%, 48% and 88% compared to 7%,
respectively). Subsequently, we have analyzed the RNA levels of
ABCB4 in normal lung, breast, kidney and liver samples and
detected expression of ABCB4 in all four tissues (Fig. 1B).
Expression of ABCB4 in liver was found at much higher rate
compared to the other three tissues. To analyze the impact of
aberrant methylation at the ABCB4 promoter, we have cloned a
918 bp promoter fragment into a luciferase reporter system and
transfected it in HeLa and HEK293 cells. In vitro methylation of
ABCB4 drastically reduced the activity (36-fold reduction) of the
promoter compared to the unmethylated promoter (Fig. 1C).
To investigate the epigenetic status of ABCB4 in human cancers in
more details, we have analyzed its aberrant methylation in six non
small cell lung cancers (A427, A549, H322, H358, HCC-15 and
H1299), seven small cell lung cancers (HTB-173, CRL-5808, CRL-
5976, CRL-5886, CRL-5898, CRL-5869, HTB-171), three breast
cancers (MCF-7, ZR-75-1 and MDA-MB-231), skin cancer (IGR-1,
SK-MEL-13, C8161), four head and neck (HN) cancers (Hep-2, UM-
SCC-14C, UM-SCC-22B and RPMI-2650), two liver cancer (Hep-B3
and Hep-2G) cell lines, HeLa and human fibroblast (HF-55) by com-
bined bisulfite restriction analysis (COBRA) and bisulfite pyrosequen-
cing of eight CpG sites (Fig. 2). Fragmentation of the PCR product by
TaqI indicates an underlying methylated ABCB4 (Fig. 2B). In vitro
methylated genomic DNA (ivm) served as a methylated control for
COBRA and pyrosequencing (Fig. 2B and C). Normal human fibroblast
(HF-55) and liver cancer cells (Hep-2G and Hep-B3) were unmethy-
lated. For lung cancer, five (A427, A549, H322, H358 andH1299) out of
six NSCLC cell lines were hypermethylated (.20% methylation) and
three (HTB-171, CRL-5898 and CRL-5896) out of seven SCLC cell lines
were methylated (Fig. 2B and 2C). Also three breast cancer cell lines
(MCF-7, ZR-75-1 and MDA-MB-231), three HN cancers (UM-SCC-
14C, UM-SCC-22B and RPMI-2650), skin cancer C8161 and HeLa
exhibited ABCB4 hypermethylation (.20%; Fig. 2B and C). Thus, 26
cancer cell lines were analyzed, of which 16 (62%) were methylated for
ABCB4 and its hypermethylation was found in different human cancer
entities including lung, breast, skin and HN cancers.
Tumor specific ABCB4 hypermethylation in primary tumors and
reduced ABCB4 expression in primary lung cancer. Next we have
Figure 1 | Epigenetic regulation of human ABCB4. (A). Structure of ABCB4 CpG island promoter on chromosome 7q21.12 and the ACBC4 protein.
Arrow marks transcriptional (11) start site and boxes mark exons of ABCB4. The ABCB4 protein consists of two ABC transporter transmembrane
regions (ABC_membrane) and two ATP-binding cassette domains (ATB_BCD). (B). ABCB4 levels in normal tissues. Expression of ABCB4was analyzed
in RNA isolated from normal lung, breast, liver and kidney samples by real-time RTPCR and normalized to GAPDHmRNA levels. (C). Promoter assay.
HEK293 cells were transfected with 1 mg of pRL-null, pRL-ABCB4 and in vitromethylated (ivm) pRL-ABCB4 promoter construct and 0.35 mg of pGL3.
Cells were isolated 24 h after transfection and studied using a dual-luciferase reporter assay.
www.nature.com/scientificreports
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Figure 2 | Methylation of ABCB4 in human cancer cell lines. (A). CpG sites at the ABCB4 promoter regions are indicated as vertical lines. The PCR
product (218 bp) with two TaqI sites (pos. 70 and 102) and eight CpG sites that were analyzed by pyrosequencing are depicted. (B). Combined
bisulfite restriction analysis of ABCB4. Bisulfite-treated DNA from the indicated cancer cell lines and in vitro methylated DNA (ivm) were amplified,
digested with TaqI (1) or mock digested (2) and resolved on 2% gels with a 100 bp marker (M); (m5methylated, u5 unmethylated). (C). Bisulfite
pyrosequencing of ABCB4. Methylation levels of eight CpGs of the bisulfite modified PCR products were analyzed by pyrosequencing.
www.nature.com/scientificreports
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analyzed the methylation levels of ABCB4 in normal human bronchial
epithelial cells (NHBEC) and human mammary epithelial cells
(HMEC) by COBRA (Fig. 3). HMEC, NHBEC and normal human
fibroblast (HF-54) show no promoter methylation ofABCB4 (Fig. 3). It
is interesting to note that the MCF-10 cell line that served as a non-
tumorigenic epithelial cell line also exhibited ABCB4 hypermethylation
(Fig. 2 and 3). However, MCF10 proliferates indefinitely in cell culture,
since it was immortalized spontaneously20. To analyze the impact of
epigenetic silencing ofABCB4 in primary cancer tissues we investigated
its hypermethylation in 46 primary NSCLC, 27 breast cancers and 10
HN cancers and several matching controls by COBRA. Representative
results are shown in Figure 3. In HN cancer only two out of ten (20%)
tumors (e.g. HNC2-T) exhibited ABCB4 hypermethylation (Fig. 3). 18
out of 46 (39%) NSCLC (e.g. NSCLC30) showed partial methylation of
ABCB4 (Fig. 3). Moreover, 11 out of 27 (41%) breast cancer tissues (e.g.
BrCa12-T) were methylated for ABCB4 (Fig. 3). All 20 analyzed
matching breast control tissue were unmethylated (e.g. BrCa12-N)
(Fig. 3). For breast cancer a significant tumor specific methylation of
ABCB4 was found (p 5 0.002, two tailed Fisher exact test).
Expression of ABCB4 was also analyzed on a lung cancer tissue
array (data not shown). 44 out of 70 (63%) of primary lung cancers
showed staining of ABCB4 and its expression was absent in 37% of
cases. The highest expression of ABCB4was observed in SCLC, while
no staining was observed in mesotheliomas. ABCB4 staining was
slightly higher in squamous cell carcinoma (18/30 or 60%) than in
adenocarcinoma (8/14 or 57%). ABCB4 staining was dominantly
cytoplasmic, but about 24% of the cases (mainly squamous cell can-
cer and SCLC) also showed nuclear staining. Neither absence of
nuclear staining nor the cytoplasmic staining correlated with the
tumor grade or clinical stage. In concordance with the methylation
frequency (39%) of ABCB4 in non small cell lung cancer, absence of
its expression was observed in 41% (18/44) of primary NSCLC.
Hypermethylation of ABCB4 is associated with its downregulation
in human cancer cell lines. 5-Aza-2’-deoxycytidine (Aza) and
zebularine (Zebu) inhibit de novo methylation21,22 and are known to
reverse hypermethylation of tumor suppressor genes, inducing their
reexpression2. We therefore treated the lung cancer cell lines A427,
A549, H322, HCC-15, HTB171 and H1299, the breast cancer cells
ZR-75-1, the HN cancer cell RPMI-2650 and the melanoma cells
SK-Mel-13 with Aza or Zebu and analyzed the ABCB4 expression
(Fig. 4). A427, A549, H322, HTB-171, ZR-75-1 and H1299 harbor a
Figure 3 | Methylation of ABCB4 in primary tumors and normal tissues. Representative COBRA analysis is shown for normal human bronchial
epithelial cells (NHBEC), human mammary epithelial cells (HMEC passage 2 and 7) and normal human fibroblast (HF-54) and primary non small cell
lung cancer (NSCLC), head and neck cancer (HNC) and breast cancer (BrCa).Mock digest (2) andTaqI digest (1) are shown. Products were resolved on
2% gel with 100 bpmarker (M). (T5 tumor, N5 corresponding normal tissue, ivm5 in vitromethylated control, m5methylated, u5 unmethylated).
www.nature.com/scientificreports
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hypermethylated ABCB4 promoter (.20% methylation Fig. 2) and
show no endogenous ABCB4 expression (Fig. 4). Treatment with
5 mM Aza or 200 mM Zebu lead to ABCB4 reexpression on RNA
level (Fig. 4A). Similar results were revealed for RPMI-2650, which
are partially methylated (35% in Fig. 2) and ABCB4 expression is
increased upon Aza treatment (Fig. 4A). HCC-15 and SK-Mel-13 are
unmethylated forABCB4 (,20%methylation; Fig. 2) and its expression
is independent of the Aza treatment (Fig. 4A). Aza treatment of the lung
cancer cells H1299 lead to ABCB4 reexpression on protein level
(Figure 4B). In addition, reexpression of ABCB4 in lung tumor
cell lines A549, A427 and H322 was accompanied by ABCB4
demethylation (data not shown). In cancer, we observed an epigenetic
silencing of ABCB4, which was reversed by Aza or Zebu treatment.
ABCB4 expression reduces colony formation and proliferation.
To functionally test ABCB4 and its ability to suppress tumor
formation, we performed colony formation and proliferation
assays (Fig. 5). Therefore, we transfected A427, A549 and H322
with an ABCB4 expression- or empty control construct (pEGFP)
and selected with G418 for three weeks. Colonies that formed were
Giemsa stained and representative pictures are shown (Fig. 5A). In all
three cancer cell lines ABCB4 is methylated (Fig. 2). Ectopic
Figure 4 | ABCB4 expression in cancer cells, reexpression underDNMT inhibitor treatment. (A). Expression analysis ofABCB4 is shown after 5-aza-2’-
deoxycytidine (Aza) and zebularine (Zebu) treatments in lung cancer cell lines A427, A549, H322, HCC-15 and HTB-171, breast cancer ZR-75-1,
head and neck cancer RPMI-2650 andmelanoma SK-Mel-13.ABCB4 (185 bp) andACTB (226 bp) expression was analyzed by RT-PCR after four days of
Aza or Zebu treatment on 2% gel with 100 bp marker (M). (B). Lung cancer H1299 cells treated with either 5 mM Aza or 200 mM Zebu for 72 h.
Cells were blocked with 5% BSA for 1 h, followed by incubation with anti-ABCB4 antibody overnight at 4uC. Finally, cells were incubated with Alexa
Fluor 488-conjugated secondary antibody and nuclei were stained with DAPI. Representative images are shown.
www.nature.com/scientificreports
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expression of ABCB4 in A549, H322 and A427 reduces the number
of colonies (Fig. 5B). For H322 and A427 this growth suppressive
effect was significant (p , 0.002 and p , 0.004, respectively; two
tailed t-test). In addition, proliferation was also significantly reduced
in A549 cells (p , 0.0006; Fig. 5C). These data suggest that ABCB4
exhibits a tumor suppressive function in human lung cancer cells.
Epigenetic silencing of Abcb4 in mouse cancer. Subsequently, we
have analyzed the methylation status and expression of the murine
Abcb4 gene (Fig. 6). Abcb4 is localized on chromosome 5qA1 and is
transcribed from a 402 bp long CpG island promoter at position
8893614 to 8894015 (Fig. 6A). We have analyzed the methylation
in normal mouse tissues (spleen, kidney, lung and liver) and in the
murine cell lines: Lewis lung cancer 1 (LLC1), NIH3T3,
teratocarcinoma F9 and Ltk- (Fig. 6B). Interestingly, in normal
tissues Abcb4 was unmethylated, but in three cell lines (LLC1,
NIH3T3 and Ltk-) its hypermethylation was detected (Fig. 6B).
NIH3T3 are primary mouse embryonic fibroblast cells, which were
spontaneously immortalized and Ltk- was derived from the L929
murine fibrosarcoma cells. Moreover, we have analyzed the
expression of Abcb4 by RT-PCR (Fig. 6C). In normal tissues Abcb4
expression was revealed, however in LLC1 and Ltk- expression of
Abcb4 was silenced. Thus, our data suggest that epigenetic silencing
of Abcb4 occurred also in pathogenesis of murine cancer.
Discussion
In our study, we have identified the ATP-binding cassette sub-family
B member 4 (ABCB4) as novel epigenetically inactivated target gene
in human cancer. Hypermethylation of ABCB4 was found in several
epithelial cancer entities including lung, breast, head and neck (HN),
skin and cervix cancer. We also observed that aberrant methylation
of ABCB4 is also frequently found in primary NSCLC (39%), breast
cancers (41%) andHN cancer (20%). In concordance with its methy-
lation frequency absence of ABCB4 expression was observed in 41%
primaryNSCLC. To our knowledge hypermethylation ofABCB4was
not reported in cancer previously. Methylation of ABCB1 (MDR1)
has been reported in breast cancer, HN cancer and other cancers23–26.
Overexpression of several ABC transporter in cancer has been
reported, however for ABCB4 and several other members
(ABCA7, ABCA12, ABCB2, ABCB5 and ABCD1) downregulation
in melanoma cell lines compared to normal melanocytes was
revealed27. Thus, it will be interesting to analyze the methylation
status of ABCB4 in primary melanomas.
We have analyzed the expression of ABCB4 in human tissues and
observed the highest mRNA levels in liver. ABCB4 expression was
also found in normal breast, lung and kidney. This is in accordance
with the previous observation that ABCB4 is highly expressed in
human liver, but ABCB4 expression was found in other normal
samples (e.g. heart and muscle)13. In normal human bronchial epi-
thelial cells, mammary epithelial cells and fibroblast ABCB4 was
unmethylated, but in primary tumor tissues aberrant promoter
methylation of ABCB4 was revealed (Fig. 3). In MCF10 cells that
are utilized as a non-tumorigenic epithelial cell line, hypermethyla-
tion of ABCB4 was found. Since MCF10 cells immortalized sponta-
neously and therefore proliferate indefinitely in cell culture20,MCF10
cannot be considered as normal human mammary epithelial cells.
Normal breast epithelial cells undergo cellular senescence after few
passages20,28,29. InMCF10 cells promoter hypermethylation of several
tumor repressive genes, including PTEN, p73, MGMT and cadherin
(CDH1 andCDH13) has been reported30. Expression ofmouseAbcb4
was also observed in all normal tissues including heart, liver, lung and
kidney (Fig. 6). In these tissues the Abcb4 CpG island was unmethy-
Figure 5 | Overexpression of ABCB4 reduces colony formation and proliferation in lung cancer cell lines. (A). A549, A427 and H322 lung cancer cell
lines were transfected with the ABCB4 expression construct or empty vector (pEGFP-C1), selected with G418 for 28 days and Giemsa stained. (B).
Experiment was repeated three times and mean colony numbers with according SD are shown for A549, A427 and H322 cells. (C). Cell proliferation of
A549 cells was evaluated by bromodeoxyuridine (BrdU) incorporation assay. BrdU incorporation was assessed by an ELISA reader. P values were
calculated using two tailed paired t-test.
www.nature.com/scientificreports
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lated. We have also analyzed the methylation levels of ABCB4, in
primary normal human liver tissues (data not shown). However,
in these liver tissues and in the liver cancer cell lines Hep-B3 and
Hep-2G no aberrant methylation of ABCB4 was found (Fig. 2 and
data not shown). Considering the ABCB4 transporter function of
phospholipids from liver hepatocytes into bile, a high tissue spe-
cific expression of ABCB4 in liver cells was expected and observed
(Fig. 1). Mutations of ABCB4 are associated with progressive
familial intrahepatic cholestasis type 3, low phospholipid asso-
ciated cholelithiasis and found in women with intrahepatic cho-
lestasis of pregnancy7–9,11,12. However, some patients with ABCB4
mutations also develop liver fibrosis, liver cirrhosis or cholangio-
carcinoma10,31,32. Cholangiocarcinomas are malignant epithelial
liver tumors with a poor prognosis and arise from the intra-
and extra-hepatic bile ducts33. Since promoter hypermethylation
of tumor associated genes has been reported in cholangiocarci-
noma33,34, it could be important to investigate the methylation
status of ABCB4 in this specific liver cancer entity. Abcb4 knock
out mice develop chronic portal inflammation and bile duct pro-
liferation with progression to liver fibrosis and hepatocellular car-
cinoma35. Other tumors in Abcb4 knock out mice have not been
reported yet.
By using 5-aza-2’-deoxycytidine and zebularine treatments we
were able to reexpress and demethylate ABCB4 (Fig. 4 and data
not shown). Moreover, methylation of the ABCB4 promoter in vitro
reduces its activity dramatically (Fig. 1). These results confirm that
downregulation of ABCB4 in cancer cells is due to its promoter
hypermethylation. Aza (Decitabine) and its derivatives (e.g.
Vidaza) are used for therapies of blood cancers36.
To verify the ability of ABCB4 to suppress tumor growth like, we
performed colony formation and proliferation assays in lung cancer
cell lines (Fig. 5). Our results show that ABCB4 significantly sup-
presses colony growth in H322 and A427 cancer cells, in which
ABCB4 is downregulated and inactivated by aberrant promoter
methylation (Fig. 2 and Fig. 4). In A549 cells which show lower
promoter hypermethylation levels compared to the other two cell
lines growth suppression was less prominent, however proliferation
was significantly reduced (Fig. 5C). Still, the exact function of ABCB4
Figure 6 | Epigenetic regulation of murine Abcb4. (A). Genomic organization of Abcb4 CpG island on chromosome 5qA1. Transcriptional start, CpG
sites andCOBRAprimers are depicted. The PCR product (148 bp) with theTaqI site (pos. 42) is indicated. (B).Methylation analysis ofAbcb4 byCOBRA.
Bisulfite converted DNA was amplified and PCR products were digested with TaqI (1) or mock-treated (2). Methylation status of Abcb4 is
indicated (m5methylated, u5 unmethylated). (C). Expression analysis of murine Abcb4 in heart, liver, lung and kidney and in murine cancer cell lines
LLC1 and Ltk-. Expression of Abcb4 (200 bp) and Gapdh (156 bp) was analyzed by RT-PCR on a 2% gel.
www.nature.com/scientificreports
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in lung and breast epithelial cells has not been analyzed in detail. In
ovarian cancer the resistance of ovarian carcinoma cells to cisplatin is
notmediated by ABCB46. Thus it will be interesting to further dissect
the role of ABCB4 in the pathogenesis of cancer.
In summary we demonstrate that the ATP-binding cassette sub-
family B member 4 gene is frequently hypermethylated in human
and murine cancers. Moreover aberrant methylation was frequently
observed in primary lung and breast cancer samples. Demethylation
of ABCB4 is accompanied by its reexpression in cancer cell lines.
Furthermore, ectopic expression of ABCB4 suppresses colony
formation in lung cancer cells. Future research will elucidate the
exact function of ABCB4 during carcinogenesis. It will be interesting
to evaluate if aberrant ABCB4 methylation may represent a novel
biomarker for prognostic or diagnostic purposes in human cancer.
Methods
Tissue and cell lines. Primary cancer tissues and cancer cell lines were previously
published15–17. All patients signed informed consent at initial clinical investigation.
The study was approved by the local ethic committees (City of Hope Medical Center,
Duarte, USA and Martin-Luther University, Halle, Germany). Mice tissues were
obtained from C57/BL6 mouse strain. All cell lines were cultured in humidified
atmosphere (37uC) with 5% CO2 and 1 3 Penicillin/Streptomycin in according
medium. Cells were transfected with 4 mg or 10 mg of constructs for 3.5 or 10 cm
plates, respectively using Polyethylenimine (Sigma Aldrich) or Turbofect (Fermentas
GmbH, St.Leon-Rot, Germany).
Cell Proliferation assay. Cell proliferation was evaluated by BrdU incorporation
using Cell Proliferation ELISA colorimetric kit (Roche Diagnostics) according to the
manufacturer’s protocol. A549 cells were transfected with ABCB4-overexpression
vector were seeded at a density of 103 103/well in 96-well plates. After 24 h cells were
starved in serum-free DMEM for further 24 h. BrdU was added to the cells and
incubated for 4 h at 37uC. After removal of culture medium the cells were fixed and
anti-BrdU antibody was added followed by the substrate. Finally BrdU incorporation
was assessed by an ELISA reader.
Methylation analysis. DNA was isolated by phenol-chloroform extraction and then
bisulfite treated prior to COBRA analysis and pyrosequencing18. 200 ng were
subsequently used for PCR with primer ABCB4BSU1
(GAGTAAAGTTTAGGTTTTTTTGTTGTAG) and 5’-biotinylated primer
ABCB4BSL1Bio (CCTCAAAACCAAATACACCCTCTCC). Products were digested
with 0.5 mlTaqI (Fermentas GmbH, St.Leon-Rot, Germany) 1 h at 65uC and resolved
on 2% TBE gel. Methylation status was quantified utilizing the primer ABCB4BSseq
(TTTAGAGGTTTTGTTAGATA) and PyroMark Q24 (Qiagen, Hilden, Germany).
Eight CpGs are included in the analyzed region ofABCB4 and meanmethylation was
calculated. For mouse Abcb4 the forward primer mABCB4BSU1
(GTGAAGTTTAGGTGAGGGAGGA) and the reverse primer mABCB4BSL1
(ACTACCTAAAAAAAAAAACCTCCAAA) were used and for in vitromethylation
of genomic DNA M.SssI methylase was utilized (NEB, Frankfurt, Germany).
Expression analysis. RNA was isolated using the Isol-RNA lysis procedure (5 Prime,
Hamburg, Germany). 25 mg of breast, kidney, liver and lung RNA of normal human
samples were obtained fromAgilent Technologies (Waldbronn, Germany). RNAwas
DNase (Fermentas GmbH, St.Leon-Rot, Germany) digested and then reversely








CCCCGGCATCGAAGGTGGAA were utilized. Quantitative PCR (qRT-PCR) was
performed in triplicates with PerfeCTa SYBRH Green (Quanta BioSciences,
Gaithersburg, USA) using Rotor-Gene 3000 (Corbett Research, Qiagen, Hilden,
Germany).
Constructs. The cDNA of human ABCB4 was obtained as a full length cDNA vector
IRATp970F09103D (Accession Number: BC042531; 4035 bp in pBluesriptR;
imaGenes GmbH, Berlin, Germany) and the ORF of ABCB4was cloned into the SacII
and XmaI sites of pEGFP-C1. The ABCB4 promoter was amplified from genomic
DNA and cloned into pRLnull (Promega, Mannheim, Germany). Therefore a 918 bp
promoter fragment was obtained by PCR with primers ABCB4Bgl2U1:
GAGTCTTTTGGGAAGAGTGTGGAGGAATTA and ABCB4EcoRIL1:
GAATTCGCGCGTGTCTGGCAGG and cloned into the BglII and EcoRI sites of
pRLnull. In vitro methylation of the promoter construct was done with M.SssI
methylase (NEB, Frankfurt, Germany).
Promoter assay. HEK293 or HeLa cells were transfected with 1 mg of pRL-ABCB4
promoter construct and 0.35 mg of pGL3. Cells were isolated 24 h after transfection
and studied using Dual-Luciferase Reporter Assay (Promega, Mannheim, Germany).
Immunocytochemistry. Cells were seeded on chamber slides and treated with either
5 mM azacytidine or 200 mM zebularine for 72 h. After washing with PBS, cells were
fixed with acetone-methanol (151) for 20 min at 220uC. Then cells were blocked
with 5% BSA for 1 h, followed by incubation with anti-ABCB4 antibody (LifeSpan
LS-B5729, 15200) at 4uC overnight. Finally, cells were incubated with Alexa Fluor
488-conjugated secondary antibody, nuclei were stained with DAPI and mounted
with fluorescent mounting media (Dako Cytomation, Glostrup, Denmark).
Immunohistochemistry. Lung cancer tissue array were purchased from Pantomics,
Inc. (Richmond, CA, USA). In brief, slides were treated with high pH antigen retrieval
buffer. Rabbit anti-human ABCB4 (15200; LS-B5729, lifespan biosciences, USA) and
normal rabbit serum were used for stainings. Slides were incubated with ABCB4
antibody at 4uC overnight. After extensive washing, sections were incubate with
secondary antibody, followed by stainingwith vector DAB (Vector Laboratories). The
slides were washed and counterstained with hematoxylin for 5 min. All slides were
analyzed under the Hamamatsu NDP slide scanner (Hamamatsu Nanozoomer
2.0HT) and its viewing platform (NDP. Viewer).
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